Interaction of ketoprofen and frusemide in man


Department of Clinical Pharmacology, St. Bartholomew’s Hospital, West Smithfield, London EC1A 7BE, UK

Summary: The effects of ketoprofen on frusemide-induced diuresis, natriuresis and renin release were studied in 12 healthy male volunteers. Each received frusemide 40 mg once daily with either ketoprofen 100 mg twice daily or placebo for two periods of 5 days separated by a treatment-free period according to a randomized, double-blind, cross-over study design. Ketoprofen significantly reduced frusemide-induced diuresis on Day 1 but not on Day 5 of treatment. The natriuresis induced by frusemide on Day 1 or Day 5 of treatment did not differ significantly whether ketoprofen or placebo was administered, although the mean urinary sodium excretion values were consistently lower following ketoprofen. Ketoprofen did not affect the kaliuretic response to frusemide on Day 1 or Day 5 of treatment. The increase in plasma renin activity after frusemide was inhibited by ketoprofen on both Day 1 and Day 5. These results suggest that ketoprofen reduces the diuresis and renin release induced by frusemide, but that the reduction in diuretic response may become less important after their repeated coadministration.

Introduction

Conflicting results have been obtained with respect to the effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on frusemide-induced diuresis and natriuresis, with a blunting1-4 or no change5-7 being reported. NSAIDs inhibit the early increase in plasma renin activity (PRA) which follows frusemide administration.1-36,7 Ketoprofen is a propionic acid derivative which has been shown to be safe and effective in the symptomatic treatment of rheumatoid and osteoarthritic diseases.8,9 There is no information available on the interaction of ketoprofen with frusemide. The absence of an interaction would make ketoprofen a NSAID of first choice when coadministration with frusemide is necessary.

This study was designed to investigate the effects of ketoprofen on frusemide-induced diuresis, natriuresis, and renin release following single and multiple doses of both drugs in healthy volunteers.

Methods

Twelve healthy male volunteers, aged 20–34 years (mean age 24) and within 10% of their ideal body weight, gave informed written consent to the study which was approved by the Ethical Committee of the City and Hackney District Health Authority. They were non-smokers and drank no alcohol during the trial periods. They were on no medication for at least one week prior to the start of the study and only the study medications were allowed during the study.

Each subject was randomly allocated to receive frusemide (40 mg once daily) together with either ketoprofen (100 mg capsule twice daily) or a matching placebo for 5 days according to a double-blind, cross-over design, the two treatment periods being separated by 9 days. Dietary advice was given in an attempt to moderate their intake of foods high in sodium and potassium for 5 days prior to and during the whole of each treatment period. Water intake was not limited but they were instructed to drink at least 2 litres of fluid daily. Twenty-four hour urine collections were made just before the start of each treatment period to assess sodium and potassium excretion and thus the approximate dietary intake of sodium and potassium of the volunteers.

The subjects attended on the mornings of Day 1 and Day 5 of each treatment period after fasting from 22:00 h the previous evening. A standard light breakfast without caffeine was taken. They
assumed a supine position for 30 minutes after which a blood sample was drawn for measurement of PRA. After emptying their bladders, they took frusemide and either ketoprofen or placebo with 100 ml water. Following this, they drank 100 ml water hourly for the next 5 hours. Another blood sample for PRA was taken at 1 hour post-dosing, after a 30 minute period of supine rest. Hourly total urine collections were made during the first 6 hours after dosing. The subjects were then allowed home to complete their 24 hour urine collections.

Urine volumes were recorded and 10 ml aliquots stored at −20°C until analysis for sodium and potassium. Blood samples for measurement of PRA were collected into tubes containing sodium ethylenediamine tetra-acetate (EDTA) and kept on ice. After centrifugation at 4°C, the plasma was separated immediately and stored at −20°C until analysis. PRA was measured by radioimmunoassay of angiotensin I (AI) generated under standard conditions and was expressed as pmol of angiotensin I generated h⁻¹ℓ⁻¹ of plasma at pH 7 and at 37°C. Urinary sodium and potassium concentrations were analysed by automated flame photometry.

The hourly total urine volumes, sodium and potassium excretion in the first 6 hours after drug administration were analysed using multiple linear regression analysis with treatment, time or measurement and subjects included as independent variables, employing the dummy variable technique. Student’s paired t test was used to examine the treatment effect on PRA, 24 hour urine volumes, sodium and potassium excretion.

Figure 1 Cumulative urinary volume (ml), sodium and potassium excretion (mmol) following administration of frusemide 40 mg with either placebo (---O--) or ketoprofen 100 mg (---●--) on Day 1 of the treatment period. Each point represents the mean value (± s.e.m.) of 12 subjects.

Figure 2 Cumulative urinary volume (ml), sodium and potassium excretion (mmol) following administration of frusemide 40 mg with either placebo (---O--) or ketoprofen 100 mg (---●--) on Day 5 of the treatment period. Each point represents the mean value (± s.e.m.) of 12 subjects.
Figure 3  Plasma renin activity (PRA pmol A1/l/h) before and after administration of frusemide 40 mg in the presence of placebo or ketoprofen 100 mg. The horizontal bars indicate the mean values of the 12 subjects.

Results

Twenty-four hour sodium excretion values on the day prior to each treatment period were similar: 113 ± 93 mmol (mean ± s.d.) prior to placebo and 117 ± 79 mmol prior to ketoprofen. The potassium excretion values were 38 ± 14 and 50 ± 26 mmol respectively. These differences were not significant.

Ketoprofen, when compared with placebo, significantly reduced frusemide-induced diuresis over the 6 hours after drug administration (mean difference = −67 ml, \(P < 0.05\)) and the 24 hour urine output (mean difference = −651 ml, \(P < 0.05\)) on Day 1 (Figure 1). On Day 5 of treatment (Figure 2), the changes did not reach significance.

The natriuresis induced by frusemide on Day 1 or Day 5 of treatment did not differ significantly whether ketoprofen or placebo was administered, although the mean urinary sodium excretion values were consistently lower following ketoprofen (Figures 1 and 2).

Similar changes were seen for frusemide-induced kaliuresis although the magnitude of the mean differences was much smaller (Figures 1 and 2).

Frusemide, when administered with placebo, significantly increased PRA over basal values on both Day 1 (mean difference = 183 pmol/l/h, \(P < 0.05\)) and Day 5 (mean difference = 355 pmol/l/h, \(P < 0.01\)) of the treatment period. Ketoprofen abolished this frusemide-induced rise in PRA on both days (Figure 3).

Discussion

The results of this study demonstrated that ketoprofen suppressed frusemide-induced diuresis and increase in PRA following concomitant administration of single doses of both drugs. On Day 5 of treatment, however, ketoprofen had no significant effect on diuresis while PRA remained suppressed. Ketoprofen did not have a significant effect on the natriuretic response although the mean urinary excretion values were consistently lower when ketoprofen was administered. These results were obtained with doses and route of administration of frusemide and ketoprofen which are commonly used in every day clinical practice. We chose to study for any interaction after both drugs were administered simultaneously because patients commonly take their medication together and the times to peak concentration of the drugs were comparable.\(^{10,11}\)

The interference by NSAIDs with the diuresis and natriuresis induced by frusemide has previously been demonstrated by others\(^{1-4}\) and is believed to be due to inhibition of renal prostaglandins by NSAIDs. However, other investigators...
References


Acknowledgements

We thank Rhone Poulenc for financial assistance and supplying the study medications.
Interaction of ketoprofen and frusemide in man.


doi: 10.1136/pgmj.67.789.655

Updated information and services can be found at:
http://pmj.bmj.com/content/67/789/655

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/